NCT01629355

Brief Summary

The purpose of this study is to study the predictive value of SensoDetect-BERA as a diagnostic tool in clinical practice for schizophrenia and bipolar disorder.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2012

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 6, 2012

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 27, 2012

Completed
4 days until next milestone

Study Start

First participant enrolled

July 1, 2012

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

September 1, 2015

Status Verified

August 1, 2015

Enrollment Period

2.8 years

First QC Date

June 6, 2012

Last Update Submit

August 31, 2015

Conditions

Keywords

Auditory Brainstem ResponseABRSD-BERA

Outcome Measures

Primary Outcomes (1)

  • SD-BERA patterns identified by SensoDetect using specific software

    The Auditory Brainstem Response examination (SD-BERA) will be conducted once for each patient following his/her inclusion in the study

    Brainstem potential patterns following an array of acoustic stimuli during a 25 min. examination

Study Arms (4)

Schizophrenia

Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.

ADHD

Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.

Bipolar disorder

Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.

Healthy controls

Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients recruited from the University Hospital of North Norway and the General Practice Clinic in Balsfjord, Troms, Norway. Healthy controls from North Norway.

You may qualify if:

  • Best-practise diagnosed schizophrenia, bipolar disorder or ADHD
  • Diagnosed since at least one year prior to enrollment.

You may not qualify if:

  • Serious hearing loss
  • Severe ongoing alcohol abuse or drug abuse
  • Diagnosed psychiatric comorbidity
  • Brain injury following cranial trauma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Balsfjord Legekontor

Balsfjord, Troms, Norway

Location

University Hospital North Norway

Tromsø, Troms, 9009, Norway

Location

Related Publications (1)

  • Wahlstrom V, Ahlander F, Wynn R. Auditory brainstem response as a diagnostic tool for patients suffering from schizophrenia, attention deficit hyperactivity disorder, and bipolar disorder: protocol. JMIR Res Protoc. 2015 Feb 12;4(1):e16. doi: 10.2196/resprot.3880.

Related Links

MeSH Terms

Conditions

Bipolar DisorderSchizophreniaAttention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental DisordersSchizophrenia Spectrum and Other Psychotic DisordersAttention Deficit and Disruptive Behavior DisordersNeurodevelopmental Disorders

Study Officials

  • Rolf Wynn, M.D., Ph.D.

    University Hospital of North Norway

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 6, 2012

First Posted

June 27, 2012

Study Start

July 1, 2012

Primary Completion

May 1, 2015

Study Completion

August 1, 2015

Last Updated

September 1, 2015

Record last verified: 2015-08

Locations